Skye Bioscience, Inc. SKYE 深 沪
等待开盘 08-09 09:30:00 美东时间
3.45
-0.100
-2.82%
华盛通- 最 高3.5046
- 今 开3.50
- 成交量 21.52万股
- 最 低 3.35
- 昨 收 3.55
- 总市值 1.07亿
- 52周最高 7.47
- 市盈率 静 --
- 换手率 0.69%
- 52周最低 1.14
- 委 比 12.57%
- 总股本 3098.44万
- 历史最高 17.6473
- 量 比 0.74
- 振 幅 4.35%
- 历史最低 1.14
- 每 手 1
- 风险率 3.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Skye Bioscience Q2 EPS $(0.44) Misses $(0.31) Estimate
Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.31) by 40.58 percent. This is a 120 percent decrease over losses of $(0.20) per share from
08-08 04:45
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Skye Bioscience will host a conference call on August 7, 2025, at 1:30 p.m. PT/4:30 p.m. ET, to discuss its second quarter 2025 financial results and business update. The webcast and materials will be available on the company's Investor Relations website. Skye is focused on developing new therapeutic pathways for metabolic health and is currently conducting a Phase 2 clinical trial for nimacimab in obesity.
07-30 11:00
美股牛股 | 纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%
纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%，皮炎药物临床试验结果良好；安霸拟考虑出售公司，隔夜涨超20%>>
06-25 19:15
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
JMP Securities Reiterates Market Outperform on Skye Bioscience, Maintains $15 Price Target
JMP Securities analyst Jonathan Wolleben reiterates Skye Bioscience (NASDAQ:SKYE) with a Market Outperform and maintains $15 price target.
06-24 21:47
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
Skye Bioscience, a biotech company focused on metabolic health, will present new data on its CB1 inhibitor nimacimab at the ADA 85th Scientific Sessions in Chicago (June 20-23, 2025). The company will participate in multiple forums, including an Evercore panel, a symposium presentation on nimacimab's mechanistic insights in obesity, and a poster presentation highlighting its effects in diet-induced obesity mouse models. Nimacimab, a peripherally-...
06-17 11:00
Brand Engagement Network Taps Hospitality Market With AI Concierge at The Dvin Resort
Brand Engagement Network Inc. (BEN) (NASDAQ:BNAI), an innovator in AI-powered customer engagement, announced it has entered into a formal agreement with Seven Visions Resort & Places, The Dvin (The Dvin), to develop
05-15 18:07
Skye Bioscience Q1 2025: Progress in Obesity Treatment
Skye Bioscience, Inc. ( ($SKYE) ) has released its Q1 earnings. Here is a break...
05-09 13:52
